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Abstract 
Background: Antiretroviral therapy (ART) scale-up in sub-Saharan Africa (SSA) combined with weak 
routine virological monitoring has driven increasing HIV drug resistance. We investigated ART failure, 
drug resistance and early mortality among hospital inpatients in Malawi.  
Methods: An observational cohort study nested in a trial of urine-based TB screening in unselected 
HIV-positive adults followed up for 56-days. Patients taking ART for ≥6 months at hospital admission 
had frozen plasma samples tested for HIV-1 viral load. Those with HIV-1 RNA ≥1000 copies per mL 
had drug resistance testing by ultra-deep sequencing, with drug resistance defined as intermediate 
or high-level resistance using the Stanford HIVDR Algorithm 
Findings: Of 1316 patients recruited in the Malawi trial site between October 2015 and September 
2017, 786 had taken ART for ≥6 months of whom 252/786 (32.1%) patients had viral load ≥1000 
copies per mL (virological failure). Mean age was 38 years, 61.5% were female and median CD4 
count was 60 cells/µL. Of 237 (94.0%) patients with HIV drug resistance results available, 195 (82.3%) 
had resistance to lamivudine, 128 (54.0%) to tenofovir and 219 (92.4%) to efavirenz. Resistance to at 
least 2 drugs was common (196/237, 82.7%) and this was associated with increased 2-month 
mortality (adjusted hazard ratio 1.7, 95% CI 1.2-2.4, p=0.004). 
Interpretation: Interventions are urgently needed and should target ART clinic, hospital and post-
hospital care, including differentiated care focusing on patients with advanced HIV, rapid viral load 
testing and routine access to drug resistance testing. Prompt diagnosis and switching to alternative 
ART could reduce early mortality among HIV-positive inpatients. 
Funding: Joint Global Health Trials Scheme of the Medical Research Council, the UK Department for 
International Development, and the Wellcome Trust. 
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Research in Context 
Evidence before this study: We searched MEDLINE for studies that investigated virological failure 
and/or HIV drug resistance in HIV-positive patients on antiretroviral therapy (ART) who are hospital 
inpatients in Africa, published between Jan 1, 2005, (ART was not in widespread use prior to this), to 
Jan 1 2020. We combined search terms for HIV (“HIV”, “HIV-1”, “Human immunodeficiency virus” or 
“AIDS”) with terms for virological failure (“virological failure”, “viral failure”, “failure”, “antiretroviral 
failure”, “treatment failure” or “ART failure”) or resistance (“resistance”, “drug resistance”, “HIV 
resistance”, “antiretroviral resistance”, or “ART resistance”) with terms for hospital inpatient 
(“hospital”, “inpatient”, “in-patient”, “admission” or “hospitalised”), and Africa. We only identified 1 
observational cohort study that reported prevalence of virological failure in two cohorts of 
inpatients. This study showed high prevalence of patients who were already taking ART, but had HIV-
1 viral load ≥1000 copies per mL. However, the study did not do viral load testing on all patients 
taking ART, introducing bias. There were no studies reporting HIV drug resistance among hospital 
inpatients. Other studies identified all reported data from outpatient clinics. 
Added value of this study: We performed HIV viral load testing on unselected patients admitted to 
hospital who were taking ART for at least 6 months, and looked for HIV drug resistance mutations 
for patients who had high HIV viral loads. We then assessed whether the presence of drug resistance 
was associated with mortality. Approximately one-third of inpatients taking ART had virological 
failure, and most of these patients had drug resistance to first-line ART which was associated with 
increased early mortality.  
Implications of all the evidence: ART failure and drug resistance is a major problem in hospital 
inpatients in high HIV prevalent settings. The evidence supports testing hospital inpatients for ART 
failure, ideally using a rapid HIV-1 viral load assays so results are available quickly and can be 
immediately acted upon. The high prevalence of drug resistance and association with early mortality 
suggest these patients should be switched to alterative ART, and supports development of low-cost, 
rapid assays to detect HIV drug resistance. Differentiated ART clinic care to support adherence and 
detect ART failure in advanced HIV, testing and screening for opportunistic infections and improved 
post discharge care may improve outcomes, although further evidence for such interventions will be 
needed.  
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Introduction 
Despite the unprecedented scale-up of antiretroviral therapy (ART) in high-HIV prevalence settings in 
sub-Saharan Africa (SSA), HIV remains a common cause of admission to hospital, with high early 
mortality (31% in the African region).1,2 Whilst older cohorts of HIV-positive patients from SSA were 
predominately newly diagnosed or ART naïve, more recent data suggests that patients admitted 
with advanced HIV (defined by World Health Organization [WHO] as CD4 count <200 cells/µL or 
stage 3 or 4 illness) are mostly ART experienced.3–6 
HIV drug resistance is increasingly common in SSA, with recent estimates of 10-15% prevalence for 
non-nucleoside reverse transcriptase inhibitors (NNRTIs) in untreated patients (transmitted drug 
resistance), and much higher rates (50-80% for NNRTIs) in patients failing ART.7–9 Laboratory and 
clinical capacity within SSA remains limited, however, with most countries managing patients on ART 
with infrequent viral load testing and minimal access to drug resistance testing. As distinguishing HIV 
drug resistance from alternative explanations for progressive illness on ART is usually not possible, 
patients who develop advanced HIV while established on ART either are assumed to have treatment 
failure or go undetected.  
Although most available data on HIV drug resistance come from outpatient clinics, inpatients 
represent a key target group for intensified interventions given their relatively high risks of 
treatment failure, advanced immunosuppression and high short-term mortality.10 Timely diagnosis 
and management of ART failure and drug resistance in this patient population has potential to 
contribute to the UNAIDS 95-95-95 targets set for 2030, as well as improving individual patient 
outcomes.1 Currently, few data exist describing HIV drug resistance in patients established on ART 
but admitted to hospital.  
To describe the prevalence of virological failure and HIV drug resistance, and their impact on early 
mortality in HIV-positive patients admitted to hospital in high-HIV burden settings, we undertook an 
observational cohort study nested within a large tuberculosis screening trial in SSA. 
 
Methods 
Study setting, design and procedures 
This cohort study was nested within the Rapid Urine-based Screening for Tuberculosis (TB) to 
Reduce AIDS Related Mortality in Hospitalised Patients in Africa (STAMP) trial, which recruited 
unselected (i.e. irrespective of clinical presentation), adult (aged ≥18 years) HIV-1 positive patients at 
admission to medical wards.4,11 Enrolled patients were randomised to TB screening using sputum 
testing alone, or sputum and urine testing. TB screening results were provided to clinical teams, but 
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with all patient management provided by hospital clinicians without input from study staff. All 
patients were managed as per national HIV guidelines (appendix, page 2). 
Exclusion criteria were: recent TB treatment (last 12 months) or TB preventative therapy (last 6 
months), or being unable or unwilling to provide informed consent. The study team recorded clinical 
data at admission and during hospitalisation on standardised case report forms based on patient 
interview, medical records and clinical review. Patients discharged alive were followed-up at 56-
days. Vital status was established by home visit, telephone or through next of kin for those not 
attending follow-up.  
Patients were included in this study if they were enrolled at the Malawi site (Zomba Central hospital, 
see appendix, page 3), and were taking ART for at least 6 months at admission. A random sample of 
80 patients not currently taking ART were also included to provide data on pre-treatment HIV drug 
resistance. Data on ART status at admission were collected by patient interview and confirmed by 
reviewing hand-held outpatient notes (“health passport”) and/or ART prescription. At enrolment, 
patients underwent venepuncture for CD4 cell count, haemoglobin, and plasma which was stored at 
-80˚C.  
Management of HIV was as per national HIV guidelines.12 First-line ART was tenofovir, lamivudine 
and efavirenz since 2011, and viral load monitoring was recommended routinely at 6 months, 2 
years and then 2 yearly after commencing ART, and if virological failure is clinically suspected 
(appendix, page 3). Viral load testing is not routinely done for hospital inpatients, but is mandatory 
prior to switching to second-line ART. 
All patients provided informed written consent for participation and sample storage. Retrospective 
HIV viral load and drug resistance testing was approved by the research ethics committee of the 
London School of Hygiene and Tropical Medicine, and the University of Malawi College of Medicine 
Research and Ethics Committee (COMREC). This study confirms to STROBE guidelines for 
observational studies (appendix, page 8). 
 
Laboratory methods and HIV genotyping  
HIV plasma viral load measurements from frozen plasma used Abbott RealTime HIV-1 (m2000sp) 
(Abbott Molecular Inc, IL USA) were undertaken in Malawi. For enrolled patients with virological 
failure, defined as a plasma viral load ≥1000 copies per mL, HIV-1 genotyping by ultra-deep 
sequencing was performed to detect drug resistance mutations (DRMs) in the UK.  
Nucleic acids were extracted from 230 µL of plasma using DSP Virus/Pathogen kit on the 
QIAsymphony platform and amplified using in-house HIV primer sets (gag-pol codons 691-3582, pol-
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int gag-pol codons 2696-5527, int-env (g120) gag-pol codons 5518-7374). Library preparations were 
generated using the Nextera®XT DNA Sample Preparation Kit and sequenced on Illumina MiSeq 
platform (Illumina Inc). Bioinformatic analysis was done using the “de novo” Iterative Virus 
Assembler (IVA, http://sanger-pathogens.github.io/iva). Following sequencing, samples were aligned 
using the MAFFT program (version 7, https://mafft.cbrc.jp/alignment/software/).  
HIV-1 subtype  and drug resistance mutations were analysed using the Stanford HIVdb Program 
(version 2.3.0 https://hivdb.stanford.edu/).13 Drug resistance mutations were only considered if 
present in ≥20% of viral population. The level of drug resistance was determined by adding penalty 
scores for each drug resistance mutation according to the Stanford HIVdb algorithm (version 8.8), 
with the level (1 to 5) being calculated based on the total score.14 Drug resistance was defined as 
level 4 (intermediate) or level 5 (high-level) resistant. Multidrug resistance (MDR) was defined as 
resistance to two or more first-line drugs from the first line ART regimen.15 
Statistical analysis  
Categorical data were compared using chi-square tests, continuous data using t-tests or Wilcoxon 
rank sum dependent on distribution. Mortality risk was calculated 56 days from enrolment patients 
were censored at death, 56-days or at last contact if lost to follow-up. Cox proportional hazards 
models were used to assess associations with mortality, p-values were calculated using likelihood 
ratio tests. The modelling strategy addressed the causal association between HIV multidrug 
resistance and mortality, and excluding factors on the causal pathway (most notably, CD4 cell count, 
clinical signs of advanced HIV and poor functional and nutritional status). All models were adjusted 
for STAMP trial arm.  
In the Cox regression analysis, linear association and departures from linearity of continuous 
variables with log(mortality rate) was assessed using the likelihood ratio test. For the mortality 
regression analysis, all patients with viral load <1000 copies per mL were assumed to have no drug 
resistance, and patients with virological failure but missing drug resistance data were excluded. A 
sensitivity analysis was done only including patients on ART for >12 months. Results are reported as 
hazard ratios (HR) with 95% confidence intervals (CIs) and Kaplan-Meier curves. Analyses used Stata 
version 14 (College Station, Texas, USA). For statistical analysis plan see appendix (page 13). 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. 
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Results 
Of 1316 HIV-positive patients enrolled in the STAMP trial at the Malawi site between October 2015 
and September 2017, 84·2% (n=1108) knew their HIV status, of whom 92·1% (1021) were taking 
ART, with 814 (79·7%) on ART for at least 6 months at hospital admission. 28 patients had missing 
HIV viral load measurements, leaving 786 included in the analysis (figure 1). Mean age was 41·5 
years, 32·8% were male, 98·0% (770/786) were on first-line ART and the median time on ART was 4·9 
years (IQR 2·2 to 8·1 years), with 77·1% having advanced HIV as defined by CD4 count below 200 
cells per µL or WHO stage 3 or 4 illness (table 1).  
59·5% (468/786) of patients had undetectable HIV-1 viral loads (<50 copies per mL) and 32·1% 
(252/786) had virological failure (viral load ≥1000 copies per mL, median viral load 125,603 copies 
per mL), and a further 8·4% (66/786) having low-level viraemia (between 50 and 999 copies per mL). 
Patients with virological failure were younger, more likely than other patients to be male, to have 
lower body mass index (BMI), Karnofsky scores and CD4 cell counts (60 compared to 383 cells per 
µL), with 93·6% having advanced HIV at admission. They were also more likely to receive 
antimicrobial and TB treatment as inpatients, and had a longer median length of hospitalisation (17 
compared to 14 days, table 1). Of the 16 patients on second-line ART, 6 (37·5%) had virological 
failure. 
 
Of 252 samples from patients with virological failure, 237 (94·0%) were successfully sequenced (237, 
233 and 225 had reverse transcriptase, protease and integrase genes sequenced, respectively) with 
all being HIV subtype C. 93.2% (221/237) of patients had DRMs to first or second-line drugs.  
The most common relevant NRTI DRMs were Met184Val (75·1%, n=178) and Lys65Arg/Asn (40·9%, 
n=97) conferring drug resistance to lamivudine and tenofovir respectively (table 2, figure 2).16 84 
(35·4%) patients had at least one thymidine analogue mutation (TAM), and 55 (23.2%) had at least 3 
TAMs. Resistance to lamivudine was seen in 82·3% (n=195), and tenofovir disoproxil in 54·0% 
(n=128). Resistance to other NRTIs was also common, with 76·4% (n=181) having drug resistance to 
abacavir and 25·3% (n=60) to zidovudine. In 16·9% (40/237) of patients, HIV was susceptible to all 
NRTIs, and in 67·9%, HIV was resistant to 3 or all 4 available NRTI drugs.  
NNRTI resistance was almost universal, with 92·4% (n=219) of samples resistant to efavirenz, and 
92·8% (n=220) resistant to nevirapine. The most common NNRTI mutations were Lys103Asn/Ser/His 
(39.7%, n=94), Tyr181Cys/Ile/Glu (36·7%, n=87) and Gly190Ala/Ser/Glu (41·4%, n=98). Resistance to 
newer NNRTI drugs was also common, consistent with anticipated cross-resistance, with 66·7% 
(n=158) resistant to rilpivirine, and 61·6% (n=146) resistant to etravirine.  
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PI and integrase inhibitor (INI) resistance were rare, with only 1/233 (0·4%) patient having a major PI 
mutation (Val82Ala), and two patients (0.9%) having accessory PI mutations (Gln58Glu). 2/225 
(0·9%) patients also had major INI mutations (one Gln148His, and one Thr66Ser), and 8/225 (3·6%) 
had accessory INI mutations (six Glu157Gln and two Gln95Lys). 
Overall, only 7·6% (n=18) of patients had no detectable resistance to any first-line ART drugs, with 
53·6% (n=127) having resistance to all first-line drugs, and 82·7% (n=196) to at least two drugs (table 
2, appendix page 5). Assuming patients with HIV viral load <1000 copies per mL had no drug 
resistance, the prevalence of resistance to at least two first-line ART drugs (multidrug resistance) 
was 25·4% (196/771) for patients hospitalised after taking ART for six months or longer. 8/15 
patients with viral loads between 400 and 999 copies per mL also had HIV-1 genotyping, of which 
7/8 (87·5%) had MDR. 
56-day mortality was 19·8% (156/786, 95% CI 17·2 – 22·8%), with over half (83/156, 53·2%) of deaths 
occurring after discharge from hospital. Mortality was greater in those with virological failure 
compared to those without (mortality 24·6% and 17·6% respectively, unadjusted HR 1·44 [95% CI 
1·04-1·98] p=0.028). This difference mainly reflects deaths after discharge (17.1% [95% CI 12·7-
22·6%] versus 9·1% [95% CI 6·8-12·0%], p=0·0020) with inpatient mortality similar for those with and 
without virological failure (9·1% and 9·4% respectively). 
Among 237 patients with virological failure and available HIV drug resistance genotypes, unadjusted 
mortality increased with increasing drug resistance. 2-month mortality was 5.6% in patients with no 
drug resistance, 13.0% if resistant to one drug, and 28.1% with resistance to two or more first-line 
ART drugs (multidrug resistance, MDR, p=0.041, appendix page 6).  
In analyses adjusted by STAMP trial arm only, age, sex, time on ART, advanced HIV, BMI, Karnofsky 
score, CD4 count, haemoglobin, WHO danger signs, TB treatment and virological failure were all 
strongly associated with increased mortality (table 3). HIV multidrug resistance was associated with 
increased mortality (HR 1·7, 95% CI 1·2-2·3, p=0·0024), and remained so after adjustment for age, 
sex,  time on ART, TB treatment and trial randomisation arm (adjusted HR 1·7, 95% CI 1·2-2·4, 
p=0·0042) (table 3, figure 3). There were no significant interactions between variables in the final 
model. Sensitivity analyses only including patients currently taking ART for 12 months or longer 
yielded similar results (n=724, adjusted HR 1·9, 95%CI 1·3-2·7, p=0·0011). 
In exploratory analyses, adjusting for CD4 cell count, clinical signs of advanced HIV and poor 
functional or nutritional status mitigated the association of HIV MDR and mortality, supporting their 
position on the causal pathway between multidrug resultant HIV and death, and their exclusion from 
the multivariable causal model.  
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79 samples from patients not taking ART at admission were successfully sequenced, among whom 
60 patients were ART naïve, and 19 had previously taken ART. Baseline characteristics differed 
(appendix, page 7) with patients never taking ART more likely to be male, with less advanced HIV, 
higher BMI, higher Karnofsky score and higher CD4 counts. HIV viral load was also higher in ART 
naïve patients (median 603,000 copies per mL, IQR 66,600 – 1,300,000 copies per mL). HIV drug 
resistance was uncommon among ART naïve patients, with no NRTI DRMs (table 2) but 11·7% (7/60) 
with NNRTI resistance to efavirenz and nevirapine. Among 19 patients with previous ART exposure, 
two (10·5%) had NRTI resistance to lamivudine, tenofovir and abacavir, and 8 (42·1%) had resistance 
to efavirenz. No major mutations to PIs or INIs were detected. 
 
Discussion 
Our findings show that, in Malawi, the vast majority of HIV positive inpatients knew their HIV status 
and were taking ART, in contrast to previously reported hospital cohorts.2 However, virological 
failure was common (32.1% of patients taking ART for 6 months at admission) and HIV drug 
resistance was almost universal amongst patients with virological failure (82·7% resistant to two or 
more ART drugs). Importantly, our data show the impact of HIV drug resistance with increased short-
term mortality risk. Pre-treatment drug resistance was restricted to NNRTIs, consistent with findings 
from recent African community-based surveys.7,9 
This is the first study to report virological failure and HIV drug resistance in unselected HIV positive 
patients admitted to hospital in SSA, and to report mortality outcomes. Hospital inpatients are an 
important source of information on the major causes of severe illness and death in key 
subpopulations such as people living with HIV.  Consistent with regional HIV care cascade data, our 
data show undiagnosed and untreated HIV was a less common cause of severe illness than 
previously reported, given the high proportion of patients already taking ART at admission. 
Our finding that 19·1% of all admissions among PLHIV (24·7% of patients taking ART for any 
duration) had virological failure highlights the growing importance of drug resistance and system 
weaknesses that limit diagnosis and management of virological failure before the onset of critical 
illness. Other African data also show widespread ART failure among inpatients, and to a lesser extent 
outpatients.10,17 Our data showing that drug resistance as an important cause of admissions and 
deaths are, therefore, likely to be regionally generalisable. 
In our study, virological failure was synonymous with HIV drug resistance. NNRTI resistance occurred 
in 92.4%, unsurprising given widespread use and low barrier to resistance, but resistance was more 
common than in outpatient studies.17 We also saw high rates of resistance to newer NNRTIs 
(etravirine and rilpivirine), likely due to prior exposure to nevirapine.18 NRTI resistance was also 
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common, 82.3% to lamivudine and 54.0% to tenofovir (widely used in SSA), with resistance to other 
NRTIs also widespread. The high prevalence of TAMs (35% had one or more, 23% had three or more) 
likely reflects the prior stavudine exposure. The prevalence of Lys74Ile as a compensatory mutation 
for Met184Val/Ile also suggests that these individuals had been failing first line ART for a significant 
period of time.19 Although PIs and INIs are included in alternative ART regimens,20 the lack of major 
resistance to these drug classes reflects little drug exposure and high barriers to resistance. The low 
prevalence of pre-treatment HIV drug resistance implies acquisition of drug resistance during 
treatment, most likely driven by sub-optimal adherence. We also demonstrated multidrug resistance 
in patients with low-level viraemia, the significance of which remains unclear. 
Mortality in this cohort was high, 20% by 2-months. We found markers of advanced HIV disease 
were associated with mortality. HIV drug resistance was also associated with mortality, showing a 
dose-response relationship, and multidrug resistance was independently associated with mortality. 
Viral load testing is rarely done for inpatients, and centralised testing programs with long 
turnaround times and lacking electronic laboratory management systems mean patients will have 
either died or been discharged once results are available.21 Therefore, virological failure in this study 
would have gone undetected and untreated. 
These findings suggest interventions aimed at preventing and diagnosing virological failure and drug 
resistance could reduce morbidity and mortality in patients taking ART. Prior to hospital admission, 
patients were actively attending ART clinics that failed to identify and address their ART failure and 
advanced HIV. Whilst the public health approach to ART has led to declines in HIV incidence and 
mortality, patients with advanced disease (despite engagement with clinics) may well benefit from 
differentiated care with focused approach to patients with high viral loads, including more frequent 
viral load testing, review and monitoring.22,23 This may be challenging with increased task-shifting 
and increasingly complex ART regimens and interactions, although clinical decision tools may help 
identify patients at high risk of poor outcomes.24 
Currently, HIV drug resistance testing has not been prioritised by HIV programmes in high burden 
settings in SSA. Point-of-care technologies to detect important drug resistance mutations are in 
the pipeline, and their use to guide ART choice led to improved outcomes among patients with 
pre-treatment drug resistance prior to initiation of first line ART.25,26 Our findings should 
encourage investment in resistance testing for patients with repeat high viral loads.   
In hospital, patients taking ART who have signs of advanced HIV would benefit from rapid, near-
patient testing for virological failure, for example using the Xpert HIV-1 Viral Load assay (Cepheid, 
Sunnyvale, CA, USA). Its use was recently shown to increase viral suppression and retention in 
care in South Africa.27 Patients identified as failing ART will need switching to alternative regimens 
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given high prevalence of drug resistance with adherence support. Screening and/or empirical 
treatment for opportunistic infections is also recommended by WHO advanced HIV guidelines.5 
Post-hospital care, especially for patients failing ART, should be improved. Systems to ensure post-
discharge follow-up and monitoring of patients with ART failure may help reduce the high 
mortality seen in the weeks following discharge. 
Malawi and WHO guidelines for ART introduced dolutegravir-based regimens (with tenofovir and 
lamivudine NRTI backbone) as the preferred first line ART from 2019.20,28 This has important 
implications for our findings, as dolutegravir will likely overcome the high levels of NNRTI 
resistance, has high barriers to resistance and can be co-administered with TB treatment.29,30 
However, the high prevalence of NRTI resistance (68% resistant to three or more NRTIs) suggest 
significant numbers could be on functional dolutegravir monotherapy. Data from the EARNEST 
trial demonstrated that even in the presence of predicted NRTI resistance, virological suppression 
with PI and NRTI based-regimens was good (89%).31 However, these patients were not acutely 
unwell, and recent data suggest that dolutegravir may be less potent than previously expected in 
patients with high viral loads,32 and have a lower barrier to resistance as compared with ritonavir-
boosted PIs when used as monotherapy.33 The real-world outcomes from dolutegravir-based ART 
and the impact of MDR HIV therefore remains to be established. 
The strengths of our study are that it is a large cohort nested in a clinical trial, and unselected HIV-
positive patients were enrolled, reducing bias. Furthermore, the data reflect routine clinical care in 
hospitalised patients. There are also some limitations. It is a single-centre study, although results are 
likely to be generalisable to other SSA settings. There is a small number missing data on HIV viral 
load and/or HIV drug mutations. The exclusion of patients not consenting may have underestimated 
virological failure and MDR, as these are likely to be sicker patients. We assumed that patients with 
viral loads <1000 copies per mL had no drug resistance, but the prevalence and implications of 
resistance in this group is not clear. We did not have detailed adherence information for patients. 
However, patients all self-reported taking ART and had evidence of attending ART clinics and ART 
being dispensed. Furthermore, high prevalence of drug resistance also supports that patients were 
taking drugs, as reversion to wildtype is common without drug pressure. 
In conclusion, we have found virological failure and HIV drug resistance to be extremely common in 
HIV-positive inpatients, and drug resistance was associated with increased mortality. Patients 
already established on ART with advanced HIV disease need screening for failure during hospital 
admission, ideally using rapid assays. Those identified as failing ART would likely benefit from 
switching to alternative ART (integrase or PI-based given NNRTI and NRTI resistance). Interventions 
targeting ART clinic and post-hospital care are also needed. Our findings also support the 
development of low-cost and rapid assays to detect HIV drug resistance. 
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Table 1: Patient characteristics at baseline and outcomes, stratified by virological failure 
    Overall 
HIV viral load 
<1000 copies per 
mL 
HIV viral load 
≥1000 copies per 
mL p-value 
    n=786 n=534 n=252   
Baseline 
characteristics           
Age (years) mean (SD) 41.5 (11.4) 43.1 (11.8) 38.2 (9.8) <0.0001 
Sex Male 258 (32.8%) 161 (30.1%) 97 (38.5%) 
0.020 
  Female 528 (67.2%) 373 (69.9%) 155 (61.5%) 
Time on ART median (IQR) 4.7 (2.0, 8.1) 4.6 (1.9, 8.1)  5.0 (2.5, 8.1) 0.16 
ART regimen 1st Line 770 (98.0%) 524 (98.1%) 246 (97.6%) 
0.64 
  2nd line 16 (2.0%) 10 (1.9%) 6 (2.4%) 
Advanced HIV Yes 606 (77.1%) 370 (69.3%) 236 (93.7%) <0.0001 
WHO TB 4 
symptom screen 
Yes 606 (77.1%) 467 (87.5%) 238 (94.4%)  0.0026 
Body mass index 
(kg/m2, BMI) 
mean (SD) 19.8 (4.2) 20.5 (4.2) 18.3 (3.6) <0.0001 
WHO danger sign Yes 191 (24.3%) 120 (22.5%) 71 (28.2%) 0.082 
Karnofsky score median (IQR) 60 (50, 70) 60 (50, 70) 50 (50, 60) <0.0001 
CD4 count 
(cells/µL)a median (IQR) 277 (97, 496) 383 (234, 562) 60 (17, 156) 
<0.0001 
HIV viral load 
(copies per mL) 
median (IQR) 0 (0, 14782) - - - 
Haemoglobin 
(g/l) mean (SD) 102.1 (31.0) 107.4 (31.5) 90.7 (26.8) 
<0.0001 
Treatments and outcomes         
STAMP trial 
randomisation 
arm 
Standard of 
Care 
402 (51.1%) 267 (50%) 135 (53.6%) 
0.35 
Intervention 384 (48.9%) 267 (50%) 117 (46.4%) 
Received any 
anti-microbial 
treatment Yes 
695 (88.4%)  457 (85.6%) 238 (94.4%)  0.0003 
Received TB 
treatment Yes 109 (13.9%)  66 (12.4%) 43 (17.1%)  
0.075 
Length of stay 
(days) median (IQR) 15.0 (8.0, 21.0) 14.0 (5.0, 21.0) 17.0 (14.0, 21.0) 
0.018 
Visited ART clinic 
after discharge 
Yes 475 (66.9%)  312 (64.7%) 163 (71.5%) 0.074 
Mortality at 56 
days 
  
  
Overall 156 (19.8%) 94 (17.6%) 62 (24.6%) 0.022 
During 
hospital 
admission 
73 (9.3%) 50 (9.4%) 23 (9.1%) 0.92 
After 
discharge from 
hospital 
83 (11.7%) 44 (9.1%) 39 (17.1%) 0.0019 
P-values compare HIV viral <1000 copies per mL and ≥1000 copies per mL, calculated using chi-squared 
for proportions, t-tests for means and Wilcoxson rank sum for medians. a 2 patients missing CD4 count 
results. ART Antiretroviral therapy; WHO World Health Organization; SD standard deviation; IQR 
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interquartile range. Advanced HIV defined as CD4 count <200 cells/µL or stage 3 or 4 illness. WHO 4 
symptom TB screen is defined as ≥1 of current cough, fever, weight loss or night sweats WHO Danger sign 
is as ≥1 of respiratory rate >30 per minute, temperature >39°C, heart rate >120 beats per minute and 
unable to walk unaided. 
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Table 2: HIV drug resistance by ART status at admission 
  
Taking ART ≥6 
months with HIV 
viral load ≥1000 
copies per mL (%) 
ART naïve 
(%) 
ART prior experience 
(%) 
  n=237 n=60 n=19 
Resistance to NRTIs 
lamivudine 195 (82.3) 0  2 (10.5) 
tenofovir 128 (54.0) 0 2 (10.5) 
abacavir 181 (76.4) 0 2 (10.5) 
zidovudine 60 (25.3) 0 0 
stavudine 167 (70.5) 0 2 (10.5) 
didanosine 169 (71.3) 0 2 (10.5) 
Resistance to NNRTIs 
efavirenz 219 (92.4) 7 (11.7) 8 (42.1) 
nevirapine 220 (92.8) 7 (11.7) 9 (47.4) 
rilpivirine 158 (66.7) 2 (3.3) 5 (26.3) 
etravirine 146 (61.6) 2 (3.3) 3 (15.8) 
Resistance to PIsa 
ritonavir-boosted lopinavir 1 (0.4) 0 0 
ritonavir-boosted atazanavir 0 0 0 
ritonavir-boosted darunavir 0 0 0 
Resistance to INIsb 
raltegravir 1 (0.4) 0 0 
dolutegravir 0 0 0 
 
Resistance to first-line ART 
Susceptible to all drugs 18 (7.6) 53 (88.3) 11 (57.9) 
Resistance to 1 drug 23 (9.7) 7 (11.7) 6 (31.6) 
Resistance to 2 drugs 69 (29.1) 0 0 
Resistance to 3 drugs 127 (53.6) 0 2 (10.5) 
Resistance to ≥2 drugs 196 (82.7) 0 2 (10.5) 
 
NRTI mutation 
Lys65Arg/Asn 97 (40.9) 0 1 (5.3) 
Met184Val 178 (75.1) 0 2 (10.5) 
Leu74Ile 17 (7.2) 0 0 
Leu74Val 3 (1.3) 0 0 
Thymidine analogue mutation (TAM) 
Met41Leu 37 (15.6) 0 0 
Asp67Asn 31 (13.1) 0 0 
Lys70Arg 21 (8.9) 0 0 
Leu210Trp 6 (2.5) 0 0 
Thr215Phe/Tyr 42 (17.7) 0 0 
Lys219Gln/Glu 37 (15.6) 0 0 
≥1 TAMs 84 (35.4) 0 0 
≥3 TAMs 55 (23.2) 0 0 
NNRTI mutation 
Leu100 23 (9.7) 0 1 (5.3) 
Lys103Asn/Ser/His 94 (39.7) 4 (6.7) 5 (26.3) 
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Tyr181Cys/Ile/Val 87 (36.7) 1 (1.7) 2 (10.5) 
Tyr188Leu/Cys/His 19 (8.0) 0 1 (5.3) 
Gly190Ala/Ser/Glu 98 (41.4) 0 2 (10.5) 
Met230Leu/Ile 4 (1.7) 0 0 
PI and INI mutationab 
Val82Ala 1 (0.4) 0 0 
Gln148Gln/His 1 (0.4) 0 0 
Thr66Thr/Ser 1 (0.4) 0 0 
Data represent individual participant numbers, brackets denote %. ART antiretroviral therapy; NRTI 
nucleoside reverse transcription inhibitor; NNRRTI non-nucleoside reverse transcription inhibitor; PI 
protease inhibitor; INI integrase inhibitor; TAM Thymidine analogue mutation. amissing data for 4 
patients whose protease gene was not successfully sequenced. bmissing data for 12 patients whose 
integrase gene was not successfully sequenced. 
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Table 3: Number of patients who survived and died by 56-days and univariable and multivariable Cox 
regression analysis of mortality 
  
Dieda  
n=156 
Univariable HR 
for mortality 
(95% CI) 
p-
valueg 
Multivariable 
HR for 
mortality 
(95% CI) 
p-
valueg 
Age (years)b mean (SD) 43.4 (12.8) 1.02 (1 - 1.03) 0.022 
1.02 (1.01 - 
1.04) 0.0049 
Sex Male 83 (32.2) 1  1 
 
<0.0001    Female 73 (13.8) 0.39 (0.28 - 0.53) <0.0001  
0.49 (0.35 - 
0.67) 
Time on ART 
median 
(IQR) 
3.9 (1.6, 
7.0) 0.95 (0.91 - 0.99) 0.023 
0.94 (0.90 - 
0.99) 0.016 
ART regimen 1st Line 152 (19.7) 1    
  2nd line 4 (25) 1.32 (0.49 - 3.56) 0.60   
Advanced HIV No 17 (9.4) 1    
  Yes 139 (22.9) 2.61 (1.58 - 4.32) 
 
<0.0001    
WHO 4 symptom 
TB screen No 13 (16) 1    
 Yes 143 (20.3) 1.28 (0.73 - 2.26) 0.37   
Body mass index  mean (SD) 18.3 (3.6) 0.88 (0.84 - 0.92) 
 
<0.0001    
WHO danger sign No 93 (15.6) 1    
 Yes 63 (33) 2.37 (1.72 - 3.26) 
 
<0.0001    
Karnofsky score 
median 
(IQR) 50 (40, 50) 0.94 (0.93 - 0.96) 
 
<0.0001    
CD4 countc 
median 
(IQR) 
135 (42, 
299) 
0.89 (0.86 – 
0.93)e 
 
<0.0001    
HIV viral load 
(copies per mL) 
<1000 
≥1000 
97 (17.6) 
59 (24.9) 
1 
1.44 (1.04 - 1.98) 
0.028 
  
Haemoglobin 
(g/l) mean (SD) 86.3 (29.3) 0.84 (0.80 - 0.88)f 
 
<0.0001    
Received any 
anti-microbial 
treatment 
No 17 (18.7) 1    
Yes 139 (20) 1.1 (0.67 - 1.83) 0.69   
TB treatment No 116 (17.1) 1 
 
<0.0001  
1 
0.0002   Yes 40 (36.7) 2.36 (1.65 - 3.39) 
2.12 (1.47 - 
3.06) 
Multidrug 
resistant HIVd 
No 100 (17.2) 1 
0.0024 
1  
0.0042 Yes 56 (27.6) 1.69 (1.21 - 2.34) 
1.68 (1.19 - 
2.37) 
a data represent individual participant numbers (%), mean (standard deviation) or median (interquartile 
range). b unadjusted HR for a 10 year increase in age is 1.17 (95% CI 1.02 – 1.34), adjusted HR for a 10 
year increase in age is 1.24 (95% CI 1.07 – 1.43). c CD4 count data missing for 2 patients. d defined as 
resistance to two or more first-line ART drugs, data missing for 15 patients without HIV drug resistance 
data, patients with suppressed virus (<100 copies per mL) were assumed to have no drug resistance. e HR 
is a 50 cells per mL increase in CD4 count. e HR is for a 10 g/l increase in haemoglobin. For all other 
continuous variables HR represent a one unit increase. There was no evidence for departures from 
linearity for any continuous variables. g p-values calculated using the likelihood ratio test from the Cox 
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proportional hazards model. All models adjusted for STAMP trial randomisation arm. No interactions in 
adjusted model. ART antiretroviral therapy; TB tuberculosis; WHO World Health Organization; HR hazard 
ratio. Advanced HIV defined as CD4 count <200 cells/µL or stage 3 or 4 illness. WHO 4 symptom TB screen 
is defined as ≥1 of current cough, fever, weight loss or night sweats WHO Danger sign is as ≥1 of 
respiratory rate >30 per minute, temperature >39°C, heart rate >120 beats per minute and unable to 
walk unaided. 
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1316 patients recruited from the 
Malawi site of the STAMP trial 
 
1108 (84.2%) known HIV status 
prior to admission 
208 new HIV diagnosis 
1021 (92.1%) Currently taking ART 
57 ART naïve 
30 Stopped ART 
Viral Load <1000 copies/ml: 534 
(67.9%) 
Viral Load ≥1000 copies/ml: 252 
(32.1%) 
207 ART <6 months or     
missing time on ART  
28 missing HIV viral 
load 
 
 
 
786 included in the study 
Figure 1: Study flow diagram for inclusion into this observational cohort study 
ART is antiretroviral therapy 
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Figure 2: Proportion of patients with virological failure who have HIV drug resistance mutations 
and intermediate or high level resistance to first-line ART drugs  
N=237. ART antiretroviral therapy; NRTI nucleoside reverse transcriptase inhibitor; NNRTI non-
nucleoside reverse transcriptase inhibitor; TAM Thymidine analogue mutation. 
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Figure 3: Kaplan Meier curve showing probability of death stratified by drug resistance 
Kaplan Meier curve shows time to death stratified by resistance to <2 first-line ART drugs, or 
resistance to or ≥2 first-line ART drugs (unadjusted HR 1.7, 95% CI 1.2-2.3, p=0.0024, adjusted HR 
1.7, 95% CI 1.2-2.4, p=0.0042; log-rank p=0.0002). Patients with viral loads <1000 copies per mL 
were assumed to have no resistance, 15 patients without HIV drug resistance data are excluded 
(n=771). ART antiretroviral therapy. 
 
